Sugi Predict

Sugi Predict / Compounds / SCHEMBL2173173

SCHEMBL2173173

SCHEMBL2173173

COC(=O)[C@H]1C[C@H](O)CN(C(=O)OC)[C@@H]1C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 14/20 0.62
▸ ERBB2 P04626 13/20 0.62
▸ MMP2 P08253 13/20 0.62
▸ MMP3 P08254 7/20 0.49
▸ MMP9 P14780 7/20 0.49
▸ SIGMAR1 Q99720 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ SLC1A2 P43004 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173561 1.00 ADAM10 (0.62) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL27672083 1.00 ADAM10 (0.62) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL27672084 0.93 ADAM10 (0.63) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2173068 0.88 ADAM10 (0.66) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2172970 0.86 ADAM10 (0.61) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL6025216 0.86 ADAM10 (0.68) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2172751 0.85 ADAM10 (0.55) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2173075 0.85 ADAM10 (0.62) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2176979 0.84 ADAM10 (0.61) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2176385 0.82 ADAM10 (0.59) ADAM10ERBB2MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ADAM10 25/4885ERBB2 2986/4885MMP2 4/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.